

**European Region** 





# Mpox outbreak – WHO EURO update

# EACS/ECDC Mpox webinar

21 August 2024

**Internal Document. Not for Further Distribution.** WHO/Europe Mpox Incident Management Support Team


who.int/europe

# Global Mpox Surveillance – Cases by month and region continued...

data as of 30 Jun 2024 17:00 CET

cases


Number of



World Health Organization

Note the different y – axis scales





#### 28-day Centered Moving Average of Daily MPOX Cases by Country





# The latest key updates in the EURO region (as of 15 August)

### Clade II: update

- As of 09 July 2024, a total of 27,530 cases of mpox (formerly named monkeypox) have been identified through IHR mechanisms, official public sources and TESSy, from 45 countries and areas.
- To date, **ten** confirmed mpox deaths (3 in Spain, 3 in Portugal, 2 in Belgium, 1 in Czechia, 1 in Austria) have been reported in the Region.
- For cases with case-based data, the epidemiological picture remains unchanged. 98% of reported cases are male. Of those, 97% of those with information available are MSM.

### Clade I: update as of 15 August, Sweden confirmed its first case of mpox Clade Ib.

- The Public Health Agency of Sweden confirmed one case of mpox Clade I in Stockholm
- Traveled to affected country
- The person tested positive for mpox on 14 August. The person is under the care of local authorities and isolated
- More information being collected though IHR channels.

### Latest mpox publications

European Region

Norld Health

Organization

(full list <u>here</u>)

- <u>Archived Join</u>t ECDC -<u>WHO Regional Office for Europe Mpox</u> <u>Surveillance Bulletins</u>
- <u>Standing recommendations for mpox</u> issued by the DG of the WHO in accordance with the IHR (2005)
- Report of the Review


   Committee regarding standing recom

   mendation for mpox
- Joint ECDC-WHO Regional Office for Europe Mpox surveillance Bulletin as of 11 July 2024
- <u>Multi-country outbreak of mpox,</u> <u>External situation report №35 as</u> of 12 August 2024
- Joint bimonthly surveillance report on SARS-CoV-2 and mpox in animals in the European Region, May and June 24
- <u>Strategic framework for enhancing</u> prevention and control of mpox – <u>2024-2027</u>
- <u>Mpox (Monkeypox) outbreak: Global</u> trends.

# Distribution of mpox cases in EUR Region in the past 4 weeks based on notification

World Health Organization European Region

100 cases notified in the past 4 weeks



# **Country Staging Levels in EURO**

World Health Organization European Region

Staging Levels are defined in the <u>Mpox control & elimination Policy Brief</u>:

• level 1a (n=46): countries/areas that have not yet detected a case of mpox or have not detected a case for three months or more

• level 1b (n=1): countries/areas with imported or travel-related case(s) of mpox in the human population with onset in the previous three months

• level 2 (n=15): countries/areas experiencing sustained local human-to-human transmission of mpox virus (MPXV) with indigenously acquired infection(s) with onset in the previous three months

Changes since last month:

▼ 1a: Portugal
 ▲ 2: Hungary
 ▼ 1a: Norway
 ▼ 1a: Czechia

Mpox staging levels of transmission World Health Organization as of 09 July 2024 European Region **CONFIDENTIAL** - for internal use only Change since Staging last month level increase 1bdecrease 1a Map production: 10 Jul 2024

Data source: WHO European Region IHR Database; The European Surveillance System (TESSy)

Contact: euroihr@who.int

Not included

The designations employed and the presentation of this material do not imply the expression of any opinior whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries Dotted and dashed lines on maps represent approximate locations for which there may not yet be full agreement.

# Mpox cases with international travel history within 3 weeks before onset March – June 2024 (TESSy data)

last case with intl travel history: 31 May 2024

Travel link	Cases
Spain	5
France	2
India	1
Puerto Rico	1
Thailand	1
Switzerland	1
UK	1
Total	16

**19 additional cases** report international travel but did not specify the destination: UK (8), Spain (7), Israel (2), Norway (1), Austria (1) Mpox cases with international travel within 3 weeks before onset March - June 2024

# European Region **CONFIDENTIAL** - for internal use only IND reported mpox importation(s) travel within EURO region travel outside EURO region Map production: 10 Jul 2024

Data source: The European Surveillance System (TESSy)

**Contact**: euroihr@who.int © World Health Organization The designations employed and the presentation of this material do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries. Dotted and dashed lines on maps represent approximate locations for which there may not yet be full agreement.

World Health Organization

Norld Health

Organization

**European Region** 

## Key Messages



### Latest mpox publications

#### (full list <u>here</u>)

- <u>Archived Join</u>t ECDC -<u>WHO Regional Office for Europe Mpox</u> <u>Surveillance Bulletins</u>
- Standing recommendations for mpox issued by the DG of the WHO in accordance with the IHR (2005)
- Report of the Review Committee regarding standing recom mendation for mpox
- Joint ECDC-WHO Regional Office for Europe Mpox surveillance Bulletin as of 11 July 2024
- Multi-country outbreak of mpox, External situation report №35 as of 12 August 2024
- Joint bimonthly surveillance report on SARS-CoV-2 and mpox in animals in the European Region, May and June 24
- <u>Strategic framework for enhancing</u> prevention and control of mpox – 2024-2027
- <u>Mpox (Monkeypox) outbreak: Global</u> trends.

## 1) This is not COVID

- This virus is not a respiratory virus, although some limited transmission through air could occur in special circumstance.
- We know mpox we have had >27000 cases in our communities for 2 years
- Epidemiology and transmission of Ib may be different, but lots of uncertainty still

## 2) Europe knows what to do (but are we doing it?)

- Public health authorities and affected communities have reduced transmission through advocacy awareness, vaccination (plus degree of natural immunity in key groups)
- We need to adapt according to <u>Standard Recommendations</u> e.g. which communities will have imported cases, investigation of outbreaks
- Vaccination is key, though not only prevention measure
- Though we controlled mpox, we didn't do the last mile vulnerability for Clade I as well as pulling punches on new infection in region

### 3) We need to be holistic as we respond

- Prepare for importation but also...
- Get our house in order in Europe and eliminate endemic mpx from the region
- Solidarity with Africa where currently the real problem is in terms of cases and severity and spread.

#### No hogging of vaccine! Classified as ECDC NORMAL

# Standing recommendations for mpox issued by Director-General in accordance with the IHR (2005), August 2023 - August 2024 –

#### States Parties are recommended to:

A. **Develop national mpox plans** and integrate into broader health systems. B. Strengthen and sustain testing and surveillance capacity and ensure that new cases of mpox are notified nationally and to WHO

C. Protect communities through **communication and engagement**; continue to build trust and fight stigma and discrimination. D. Invest in research to better understand mpox disease and transmission patterns, and to develop improved vaccines, tests, and treatments

E. Provide travelers with information to protect themselves and others; refrain from implementing mpox screening and testing for travelers. **F. Deliver optimal clinical care**, integrated within HIV and STI programmes, with access to treatments and measures to protect health workers and caregivers.

G. Work towards equitable access to safe, effective and quality-assured vaccines, tests and treatments for mpox.

Standing recommendations for mpox issued by the Director-General of the World Health Organization (WHO) in accordance with the International Health Regulations (2005) (IHR)





Classified as ECDC NORMAL



**European Region** 

